



# Marksans Pharma Ltd.

Date: 6<sup>th</sup> August, 2018

**BSE Limited**  
Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Sub: Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2018 and Limited Review Reports thereon.**

Dear Sir,

In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, enclosed herewith kindly find Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2018 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. 6<sup>th</sup> August, 2018 along with Limited Review Reports thereon.

The meeting commenced at 11:30 a.m. and concluded at 12:45 p.m.

You are requested to note the above in your records.

Thanking you.

Yours faithfully,  
For **Marksans Pharma Limited**

**Harshvardhan Panigrahi**  
Company Secretary & Manager – Legal



6 AUG 2018

**LIMITED REVIEW REPORT FOR THE QUARTER ENDED 30.06.2018**

**Review Report to The Board of Directors, Marksans Pharma Ltd.**

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **MARKSANS PHARMA LTD** for the quarter ended 30<sup>th</sup> June, 2018 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the accompanying unaudited financial results and other financial information for the comparative period as of and for the quarter ended 30<sup>th</sup> June, 2017 which have been presented solely based on the information compiled by the management.

**For V. S. LALPURIA & CO.**  
Chartered Accountants

**V. S. LALPURIA**  
(Proprietor)  
M.No.015926  
Place: Mumbai  
Date: 06.08.2018



6 AUG 2018

**LIMITED REVIEW REPORT FOR THE QUARTER ENDED 30.06.2018**

**Review Report to The Board of Directors, Marksans Pharma Ltd.**

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **MARKSANS PHARMA LTD** for the quarter ended 30th June, 2018 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.



We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the financial results of 3 subsidiaries included in the consolidated financial statement, whose consolidated financial results reflect total revenues of Rs. 2181.78 million and net profit of Rs.110.08 million for the quarter ended 30th June, 2018.

We have not reviewed the accompanying unaudited financial results and other financial information for the comparative period as of and for the quarter ended 30th June, 2018 which have been presented solely based on the information compiled by the management.

**For V. S. LALPURIA & CO.**  
**Chartered Accountants**

  
  
**V. S. LALPURIA**  
**(Proprietor)**  
**M.No.015926**  
**Place: Mumbai**  
**Date: 06.08.2018**

MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai-400053 [CIN:L24110MH1992PLC066364]

Telephone No.: 022-4001 2000, Fax No.:022-4001 2011, E-mail: info@marksanspharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018

(₹ in Million)

Sr. No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		3 MONTHS ENDED			Previous Year ended	3 MONTHS ENDED			Previous Year ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018	30.06.2018	31.03.2018	30.06.2017	31.03.2018
	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	
1	Revenue from Operations	931.37	868.37	523.88	2,946.62	2,352.53	1,993.18	2,210.56	9,126.92
2	Other Income	32.19	0.79	0.43	1.22	32.32		0.43	3.55
3	<b>Total Income</b>	<b>963.56</b>	<b>869.16</b>	<b>524.31</b>	<b>2,947.84</b>	<b>2,384.85</b>	<b>1,993.18</b>	<b>2,210.99</b>	<b>9,130.47</b>
4	Expenses								
	Cost of Material Consumed	425.66	462.33	272.93	1,547.43	1,005.06	546.86	1,064.97	3,486.63
	Purchase of Stock - in- trade	49.48	51.79	25.81	183.26	240.19	428.93	394.68	1,539.18
	Changes in inventories of finished goods, work-in-process and stock-in-trade	(8.22)	(24.61)	(28.75)	(37.21)	(86.35)	85.89	(196.40)	205.46
	Employee benefits expense	113.53	111.40	119.56	458.56	370.79	381.86	374.01	1,477.48
	Finance cost	14.99	25.88	13.24	76.68	23.97	34.73	19.35	102.17
	Depreciation and amortisation expense	21.22	25.39	38.06	122.51	59.64	61.92	74.46	268.38
	Other expenses	180.15	160.08	55.94	430.09	467.98	509.77	283.35	1,553.19
	<b>Total Expenses</b>	<b>796.81</b>	<b>812.26</b>	<b>496.79</b>	<b>2,781.32</b>	<b>2,081.28</b>	<b>2,049.96</b>	<b>2,014.42</b>	<b>8,632.49</b>
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>166.75</b>	<b>56.90</b>	<b>27.52</b>	<b>166.52</b>	<b>303.57</b>	<b>(56.78)</b>	<b>196.57</b>	<b>497.98</b>
6	Tax expense:								
	(1) Current Year	35.74	12.80	4.58	36.20	62.48	7.25	41.05	133.92
	(2) Earlier year	(12.15)	-	0.04	0.04	(12.15)	-	0.04	0.04
	(3) Deferred tax	4.46	0.78	11.30	6.02	4.46	0.78	11.30	6.02
	<b>Total Tax Expenses</b>	<b>28.05</b>	<b>13.58</b>	<b>15.92</b>	<b>42.26</b>	<b>54.79</b>	<b>8.03</b>	<b>52.39</b>	<b>139.98</b>
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>138.70</b>	<b>43.32</b>	<b>11.60</b>	<b>124.26</b>	<b>248.78</b>	<b>(64.81)</b>	<b>144.18</b>	<b>358.00</b>
	Other Comprehensive Income/(Loss)								
	Items that will not be reclassified to Profit or Loss	-	1.95	-	1.95	-	1.95	-	1.95
	Income tax relating to above Items that will not be reclassified to Profit or Loss	-	(0.73)	-	(0.73)	-	(0.73)	-	(0.73)
	Items that will be reclassified to profit or loss					12.98	68.33		68.33
	Income tax relating to above Items that will be reclassified to Profit or Loss								
8	<b>Other Comprehensive Income/(Loss)</b>	<b>-</b>	<b>1.22</b>	<b>-</b>	<b>1.22</b>	<b>12.98</b>	<b>69.55</b>	<b>-</b>	<b>69.55</b>
9	<b>Total Comprehensive Income for the period</b>	<b>138.70</b>	<b>44.54</b>	<b>11.60</b>	<b>125.48</b>	<b>261.76</b>	<b>4.74</b>	<b>144.18</b>	<b>427.55</b>
10	Total Comprehensive Income attributable to:-								
	Non-Controlling interests	-	-	-	-	10.35	4.06	7.80	28.61
	Owners of the Company	<b>138.70</b>	<b>44.54</b>	<b>11.60</b>	<b>125.48</b>	<b>251.41</b>	<b>0.68</b>	<b>136.38</b>	<b>398.94</b>
11	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	409.31	409.31	409.31	409.31	409.31	409.31
12	Earnings Per Share of ₹1 each								
	Basic	0.34	0.11	0.03	0.30	0.58	(0.17)	0.33	0.80
	Diluted	0.34	0.11	0.03	0.30	0.58	(0.17)	0.33	0.80

NOTES:

- The above unaudited results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 06<sup>th</sup> August, 2018. The statutory auditors have carried out a limited review of these financial results.
- The figures for the quarter ended 31st March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figure upto nine months of the relevant financial year.
- The Consolidated Financial Statements Include Financial Statements of the subsidiaries Marksans Pharma (U.K.) Limited, Marksans Pharma Inc. USA and Nova Pharmaceuticals Australasia Pty Ltd.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- Previous period's/year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current period's figures.

Place: Mumbai.  
Date: 06th August, 2018  
[www.marksanspharma.com](http://www.marksanspharma.com)



For MARKSANS PHARMA LIMITED

MARK SALDANHA  
Managing Director

